Cognitive effects of cancer and its treatments at the intersection of aging: What do we know; What do we need to know?

Seminars in Oncology

Volumn 40, Issue 6, 2013, Pages 709-725

  Mandelblatt, Jeanne S ^a   Hurria, Arti ^b   McDonald, Brenna C ^c   Saykin, Andrew J ^c   Stern, Robert A ^d   Vanmeter, John W ^e   McGuckin, Meghan ^a   Traina, Tiffani ^f   Denduluri, Neelima ^g   Turner, Scott ^e   Howard, Darlene ^h   Jacobsen, Paul B ⁱ   Ahles, Tim ^f,j  

^a GEORGETOWN UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CATECHOL METHYLTRANSFERASE; CYCLOPHOSPHAMIDE; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FLUOXETINE; INTERLEUKIN 6; METHOTREXATE; MODAFINIL; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINE; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN P53; SEROTONIN RECEPTOR; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

AGING; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; COGNITIVE DEFECT; COGNITIVE RESERVE; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; EXECUTIVE FUNCTION; FRAIL ELDERLY; FRONTAL LOBE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GERIATRIC ASSESSMENT; GERIATRIC CARE; HIGH RISK PATIENT; HIPPOCAMPUS; HUMAN; INFLAMMATION; LANGUAGE; LEARNING; LIFESTYLE; MEMORY; MILD COGNITIVE IMPAIRMENT; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SENESCENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE HOMEOSTASIS; WIDE RANGE ACHIEVEMENT TEST; WORKING MEMORY;

AGED; AGING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COGNITION; COGNITION DISORDERS; COGNITIVE RESERVE; FEMALE; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMANS;

EID: 84890330535     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.09.006     Document Type: Article

References (177)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality-All COD, Aggregated with state, total U.S. (1969-2009)-linked to county attributes-total U.S., 1969-2010 counties, National Cancer Institute, DCCPS. Accessed May 1, 2012.
2. United States Census Bureau, U.S. Department of Commerce, Economics and Statistics Administration. Population by age, sex, race and Hispanic and Latino origin for the United States. Accessed 2008, http://www.census.gov/population/ www.cen2000/briefs/phc-t9/tables/tab01.pdf. 2011.
3. P.M. Silberfarb Chemotherapy and cognitive defects in cancer patients Annu Rev Med 34 1983 35 46
4. B. Eberhardt, S. Dilger, F. Musial, U. Wedding, T. Weiss, and W.H. Miltner Short-term monitoring of cognitive functions before and during the first course of treatment J Cancer Res Clin Oncol 132 2006 234 240
5. T.A. Ahles, J.C. Root, and E.L. Ryan Cancer- and cancer treatment-associated cognitive change: an update on the state of the science J Clin Oncol 30 2012 3675 3686
6. H.S. Jim, K.M. Phillips, and S. Chait Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy J Clin Oncol 30 2012 3578 3587
7. T.A. Ahles, A.J. Saykin, and B.C. McDonald Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve J Clin Oncol 28 2010 4434 4440
8. J. Campisi Aging, cellular senescence, and cancer Annu Rev Physiol 75 2013 685 705
9. J.L. Kirkland Translating advances from the basic biology of aging into clinical application Exp Gerontol 48 2013 1 5
10. D. Head, A.Z. Snyder, L.E. Girton, J.C. Morris, and R.L. Buckner Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease Cereb Cortex 15 2005 732 739
11. T. Hedden, and J.D. Gabrieli Healthy and pathological processes in adult development: new evidence from neuroimaging of the aging brain Curr Opin Neurol 18 2005 740 747
12. A.J. Saykin, T.A. Ahles, and B.C. McDonald Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives Semin Clin Neuropsychiatry 8 2003 201 216
13. S.K. Conroy, B.C. McDonald, and D.J. Smith Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage Breast Cancer Res Treat 137 2013 493 502
14. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics,. 2013 CA Cancer J Clin 63 2013 11 30
15. American Cancer Society. Breast cancer facts & figures. 2011-2012. Atlanta: American Cancer Society, Inc. Assessed May 1, 2012
16. C.M. Bender Chemotherapy may have small to moderate negative effects on cognitive functioning Cancer Treat Rev 32 2006 316 319
17. S.J. Jansen, W. Otten, M.C. Baas-Thijssen, C.J. van de Velde, J.W. Nortier, and A.M. Stiggelbout Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients J Clin Oncol 23 2005 6623 6630
18. C. Anderson-Hanley, M.L. Sherman, R. Riggs, V.B. Agocha, and B.E. Compas Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature J Int Neuropsychol Soc 9 2003 967 982
19. D.D. Correa, and T.A. Ahles Neurocognitive changes in cancer survivors Cancer J 14 2008 396 400
20. A. Stewart, C. Bielajew, B. Collins, M. Parkinson, and E. Tomiak A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer Clin Neuropsychol 20 2006 76 89
21. B.J. Small, K.S. Rawson, and E. Walsh Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors Cancer 117 2011 1369 1376
22. P.A. Ganz, J.E. Bower, and L. Kwan Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun SUPPL. 2012 S99 S108
23. T.A. Ahles, A.J. Saykin, and C.T. Furstenberg Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma J Clin Oncol 20 2002 485 493
24. T.A. Ahles Brain vulnerability to chemotherapy toxicities Psychooncology 21 2012 1141 1148
25. V. Koppelmans, M.M. Breteler, W. Boogerd, C. Seynaeve, C. Gundy, and S.B. Schagen Neuropsychological performance in survivors of breast cancer more than. 20 years after adjuvant chemotherapy J Clin Oncol 30 2012 1080 1086
26. A. Hurria, S. Goldfarb, and C. Rosen Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective Breast Cancer Res Treat 98 2006 343 348
27. R.J. Freilich, J.Y. Delattre, A. Monjour, and L.M. DeAngelis Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients Neurology 46 1996 435 439
28. T.H. Yamada, N.L. Denburg, L.J. Beglinger, and S.K. Schultz Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy J Neuropsychiatry Clin Neurosci 22 2010 48 54
29. A. Hurria, and M. Lachs Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer? Breast Cancer Res Treat 103 2007 259 268
30. A. Hurria, C. Rosen, and C. Hudis Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study J Am Geriatr Soc 54 2006 925 931
31. A.D. Hutchinson, J.R. Hosking, G. Kichenadasse, J.K. Mattiske, and C. Wilson Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review Cancer Treat Rev 38 2012 926 934
32. J. Vardy, S. Rourke, and I.F. Tannock Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research J Clin Oncol 25 2007 2455 2463
33. J. Vardy, and I. Tannock Cognitive function after chemotherapy in adults with solid tumours Crit Rev Oncol Hematol 63 2007 183 202
34. J.S. Wefel, R. Lenzi, R.L. Theriault, R.N. Davis, and C.A. Meyers The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial Cancer 100 2004 2292 2299
35. J. Vardy, J.S. Wefel, T. Ahles, I.F. Tannock, and S.B. Schagen Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop Ann Oncol 19 2008 623 629
36. L.P. Fried, C.M. Tangen, and J. Walston Frailty in older adults: evidence for a phenotype J Gerontol A Biol Sci Med Sci 56 2001 M146 M156
37. C.A. Sarkisian, T.L. Gruenewald, B.W. John, and T.E. Seeman Preliminary evidence for subdimensions of geriatric frailty: the MacArthur study of successful aging J Am Geriatr Soc 56 2008 2292 2297
38. J.A. Avila-Funes, H. Amieva, and P. Barberger-Gateau Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study J Am Geriatr Soc 57 2009 453 461
39. J. Walston, E.C. Hadley, and L. Ferrucci Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults J Am Geriatr Soc 54 2006 991 1001
40. S.A. Sternberg, S.A. Wershof, S. Karunananthan, H. Bergman, and C.A. Mark The identification of frailty: a systematic literature review J Am Geriatr Soc 59 2011 2129 2138
41. L.J. Whalley, I.J. Deary, C.L. Appleton, and J.M. Starr Cognitive reserve and the neurobiology of cognitive aging Ageing Res Rev 3 2004 369 382
42. R. Vazzana, S. Bandinelli, and F. Lauretani Trail Making Test predicts physical impairment and mortality in older persons J Am Geriatr Soc 58 2010 719 723
43. D.R. Taaffe, T.B. Harris, L. Ferrucci, J. Rowe, and T.E. Seeman Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging J Gerontol A Biol Sci Med Sci 55 2000 M709 M715
44. J. Campisi, and F.F. d'Adda di Cellular senescence: when bad things happen to good cells Nat Rev Mol Cell Biol 8 2007 729 740
45. P.G. Nuciforo, C. Luise, M. Capra, G. Pelosi, and F.F. d'Adda di Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression Carcinogenesis 28 2007 2082 2088
46. Z.S. Tan, A.S. Beiser, and R.S. Vasan Inflammatory markers and the risk of Alzheimer disease: the Framingham Study Neurology 68 2007 1902 1908
47. S. Kesler, M. Janelsins, and D. Koovakkattu Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors Brain Behav Immun 30SUPPL. 2013 S109 S116
48. K.N. Holohan, D.K. Lahiri, B.P. Schneider, T. Foroud, and A.J. Saykin Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathway Front Genet 3 2012 323
49. S.L. Risacher, D. Wudunn, and S.M. Pepin Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints Neurobiol Aging 34 2013 1133 1144
50. S.L. Risacher, and A.J. Saykin Neuroimaging and other biomarkers for Alzheimers disease: the changing landscape of early detection Annu Rev Clin Psychol 9 2013 621 648
51. T.A. Ahles, and A.J. Saykin Candidate mechanisms for chemotherapy-induced cognitive changes Nat Rev Cancer 7 2007 192 201
52. D.H. Silverman, C.J. Dy, and S.A. Castellon Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy Breast Cancer Res Treat 103 2007 303 311
53. B.C. McDonald, S.K. Conroy, T.A. Ahles, J.D. West, and A.J. Saykin Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study Breast Cancer Res Treat 123 2010 819 828
54. B.C. McDonald, S.K. Conroy, D.J. Smith, J.D. West, and A.J. Saykin Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study Brain Behav Immun 2012
55. T.A. Ahles, A.J. Saykin, and B.C. McDonald Cognitive function in breast cancer patients prior to adjuvant treatment Breast Cancer Res Treat 110 2008 143 152
56. M. Ganguli A reduced risk of Alzheimer's disease in those who survive cancer BMJ 344 2012 e1662
57. J.A. Driver, A. Beiser, and R. Au Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study BMJ 344 2012 e1442
58. J.A. Driver, and K.P. Lu Pin1: a new genetic link between Alzheimer's disease, cancer and aging Curr Aging Sci 3 2010 158 165
59. I. Irminger-Finger Science of cancer and aging J Clin Oncol 25 2007 1844 1851
60. R. Seigers, and J.E. Fardell Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research Neurosci Biobehav Rev 35 2011 729 741
61. J. Dietrich, R. Han, Y. Yang, M. Mayer-Proschel, and M. Noble CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo J Biol 5 2006 22
62. R.E. Maccormick Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses 67 2006 212 215
63. S.M. Stemmer, J.C. Stears, B.S. Burton, R.B. Jones, and J.H. Simon White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support AJNR Am J Neuroradiol 15 1994 1267 1273
64. C. Kawas, S. Resnick, and A. Morrison A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging Neurology 48 1997 1517 1521
65. K. Yaffe, G. Sawaya, I. Lieberburg, and D. Grady Estrogen therapy in postmenopausal women: effects on cognitive function and dementia JAMA 279 1998 688 695
66. A. Paganini-Hill, and V.W. Henderson Estrogen replacement therapy and risk of Alzheimer disease Arch Intern Med 156 1996 2213 2217
67. J.L. Ross, D. Roeltgen, and G.A. Stefanatos Androgen-responsive aspects of cognition in girls with Turner syndrome J Clin Endocrinol Metab 88 2003 292 296
68. J.L. Ross, D. Roeltgen, P. Feuillan, H. Kushner, and G.B. Cutler Jr Effects of estrogen on nonverbal processing speed and motor function in girls with Turner's syndrome J Clin Endocrinol Metab 83 1998 3198 3204
69. J.L. Ross, D. Roeltgen, H. Kushner, F. Wei, and A.R. Zinn The Turner syndrome-associated neurocognitive phenotype maps to distal Xp Am J Hum Genet 67 2000 672 681
70. B.S. McEwen, and C.S. Woolley Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain Exp Gerontol 29 1994 431 436
71. R.A. Srivastava, N. Bhasin, and N. Srivastava Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen Biochem Mol Biol Int 38 1996 91 101
72. B.B. Sherwin Estrogen and cognitive aging in women Neuroscience 138 2006 1021 1026
73. J. Lee Understanding cognitive reserve through genetic epidemiology Y. Stern, Cognitive reserve 2006 Taylor & Francis New York, NY 5 34
74. R. Monastero, A.B. Cefalu, and C. Camarda Association of estrogen receptor alpha gene with Alzheimer's disease: a case-control study J Alzheimers Dis 9 2006 273 278
75. T.C. Unfer, G.M. Conterato, J.C. da Silva, M.M. Duarte, and T. Emanuelli Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women Clin Chim Acta 369 2006 73 77
76. V. Chisu, P. Manca, M. Zedda, G. Lepore, S. Gadau, and V. Farina Effects of testosterone on differentiation and oxidative stress resistance in C1300 neuroblastoma cells Neuro Endocrinol Lett 27 2006 807 812
77. D.C. Lee, J.A. Im, J.H. Kim, H.R. Lee, and J.Y. Shim Effect of long-term hormone therapy on telomere length in postmenopausal women Yonsei Med J 46 2005 471 479
78. S.A. Castellon, P.A. Ganz, J.E. Bower, L. Petersen, L. Abraham, and G.A. Greendale Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen J Clin Exp Neuropsychol 26 2004 955 969
79. C.M. Schilder, C. Seynaeve, and L.V. Beex Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial J Clin Oncol 28 2010 1294 1300
80. V.A. Jenkins, L.M. Ambroisine, L. Atkins, J. Cuzick, A. Howell, and L.J. Fallowfield Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II) Lancet Oncol 9 2008 953 961
81. C.M. Bender, S.M. Sereika, and A.M. Brufsky Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer Menopause 14 2007 995 998
82. B. Collins, J. Mackenzie, A. Stewart, C. Bielajew, and S. Verma Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study Psychooncology 18 2009 811 821
83. C.M. Schilder, P.C. Eggens, and C. Seynaeve Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study Acta Oncol 48 2009 76 85
84. C.M. Bender, K.K. Paraska, S.M. Sereika, C.M. Ryan, and S.L. Berga Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review J Pain Symptom Manage 21 2001 407 424
85. D.R. Ciocca, and L.M. Roig Estrogen receptors in human nontarget tissues: biological and clinical implications Endocr Rev 16 1995 35 62
86. V. Shilling, V. Jenkins, L. Fallowfield, and A. Howell The effects of oestrogens and anti-oestrogens on cognition Breast 10 2001 484 491
87. B.J. Deroo, and K.S. Korach Estrogen receptors and human disease J Clin Invest 116 2006 561 570
88. S.R. Kesler, J.S. Kent, and R. O'Hara Prefrontal cortex and executive function impairments in primary breast cancer Arch Neurol 68 2011 1447 1453
89. G. Joshi, C.D. Aluise, and M.P. Cole Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug Adriamycin: implications for oxidative stress-mediated chemobrain Neuroscience 166 2010 796 807
90. L. Shai, M.B. Schulze, and J.E. Manson A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes Diabetes Care 28 2005 1376 1382
91. J. Blasiak, M. Arabski, and R. Krupa Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer Mutat Res 554 2004 139 148
92. Y. Chen, P. Jungsuwadee, M. Vore, D.A. Butterfield St, and D.K. Clair Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues Mol Interv 7 2007 147 156
93. L. Migliore, R. Scarpato, F. Coppede, L. Petrozzi, U. Bonuccelli, and V. Rodilla Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients Int J Hyg Environ Health 204 2001 61 66
94. L. Migliore, I. Fontana, and F. Trippi Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients Neurobiol Aging 26 2005 567 573
95. K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis 24 2009 391 404
96. J.F. Harrison, S.B. Hollensworth, D.R. Spitz, W.C. Copeland, G.L. Wilson, and S.P. LeDoux Oxidative stress-induced apoptosis in neurons correlates with mitochondrial DNA base excision repair pathway imbalance Nucleic Acids Res 33 2005 4660 4671
97. K.W. Caldecott DNA single-strand breaks and neurodegeneration DNA Repair (Amst) 3 2004 875 882
98. R.L. Rolig, and P.J. McKinnon Linking DNA damage and neurodegeneration Trends Neurosci 23 2000 417 424
99. C.J. Wilson, C.E. Finch, and H.J. Cohen Cytokines and cognition - the case for a head-to-toe inflammatory paradigm J Am Geriatr Soc 50 2002 2041 2056
100. T.W. McAllister, T.A. Ahles, and A.J. Saykin Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments Curr Psychiatry Rep 6 2004 364 371
101. E.H. Corder, A.M. Saunders, and W.J. Strittmatter Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 1993 921 923
102. L.A. Farrer, L.A. Cupples, and J.L. Haines Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium JAMA 278 1997 1349 1356
103. S.M. Laws, R.M. Clarnette, and K. Taddei APOE-epsilon4 and APOE-491A polymorphisms in individuals with subjective memory loss Mol Psychiatry 7 2002 768 775
104. N. Nathoo, R. Chetry, J.R. van Dellen, C. Connolly, and R. Naidoo Apolipoprotein E polymorphism and outcome after closed traumatic brain injury: influence of ethnic and regional differences J Neurosurg 98 2003 302 306
105. T. Porrata-Doria, J.L. Matta, and S.F. Acevedo Apolipoprotein E allelic frequency altered in women with early-onset breast cancer Breast Cancer (Auckl) 4 2010 43 48
106. K.B. Moysich, J.L. Freudenheim, and J.A. Baker Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk Mol Carcinog 27 2000 2 9
107. C. Marzolini, E. Paus, T. Buclin, and R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33
108. V. Jenkins, L. Atkins, and L. Fallowfield Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur J Cancer 43 2007 1342 1347
109. D. Crivellari, Z. Sun, and A.S. Coates Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial J Clin Oncol 26 12 2008 1972 1979
110. P.E. Goss, J.N. Ingle, and J.L. Pater Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen J Clin Oncol 26 2008 1948 1955
111. Davies C, Pan H, Godwin J, et al. For the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group: ATLAS-10 v 5 years of adjuvant tamoxifen in ER+ disease: effects on outcome in the first and in the second decade after diagnosis. 2012 San Antonio Breast Cancer Symposium. Abstract S1-2. Presented December 5, 2012.
112. C. Davies, H. Pan, and J. Godwin Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
113. U. Lindenberger, I.E. Nagel, C. Chicherio, S.C. Li, H.R. Heekeren, and L. Backman Age-related decline in brain resources modulates genetic effects on cognitive functioning Front Neurosci 2 2008 234 244
114. P.T. Pang, H.K. Teng, and E. Zaitsev Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity Science 306 2004 487 491
115. J. Savitz, M. Solms, and R. Ramesar The molecular genetics of cognition: dopamine, COMT and BDNF Genes Brain Behav 5 2006 311 328
116. M.F. Egan, M. Kojima, and J.H. Callicott The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function Cell 112 2003 257 269
117. A.R. Hariri, T.E. Goldberg, and V.S. Mattay Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance J Neurosci 23 2003 6690 6694
118. L. Pezawas, B.A. Verchinski, and V.S. Mattay The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology J Neurosci 24 2004 10099 10102
119. Ganz PA, Castellon SA, Silverman DHS, et al. Does circulating tumor necrosis factor (TNF) play a role in postchemotherapy cerebral dysfunction in breast cancer survivors (BCS)? Abstract presented at Annual Meeting of the American Society of Clinical Oncology, Chicago; June 3, 2011.
120. Cognitive complaints in breast cancer patients: associations with therapy and cytokine markers. Abstract presented at the International Cognition and Cancer Task Force Conference Meeting, Paris; March 16, 2012.
121. R. Han, Y.M. Yang, J. Dietrich, A. Luebke, M. Mayer-Proschel, and M. Noble Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system J Biol 7 2008 12
122. H. Wu, W.N. Hait, and J.M. Yang Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells Cancer Res 63 2003 1515 1519
123. K. Jamroziak, and T. Robak Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies Hematology 9 2004 91 105
124. C.A. Meyers How chemotherapy damages the central nervous system J Biol 7 2008 11
125. S. Kalmijn, E.J. Feskens, L.J. Launer, and D. Kromhout Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men Stroke 27 1996 2230 2235
126. L. Kilander, H. Nyman, M. Boberg, and H. Lithell Cognitive function, vascular risk factors and education. A cross-sectional study based on a cohort of 70-year-old men J Intern Med 242 1997 313 321
127. E. van Exel, A.J. de Craen, and J. Gussekloo Association between high-density lipoprotein and cognitive impairment in the oldest old Ann Neurol 51 2002 716 721
128. J.N. Keller Age-related neuropathology, cognitive decline, and Alzheimer's disease Ageing Res Rev 5 2006 1 13
129. C. Hurny, J. Bernhard, and A.S. Coates Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer International Breast Cancer Study Group. Lancet 347 1996 1279 1284
130. J.E. Peelle, R. Cusack, and R.N. Henson Adjusting for global effects in voxel-based morphometry: gray matter decline in normal aging Neuroimage 60 2012 1503 1516
131. L. Bergouignan, J.P. Lefranc, M. Chupin, N. Morel, J.P. Spano, and P. Fossati Breast cancer affects both the hippocampus volume and the episodic autobiographical memory retrieval PLoS One 6 2011 e25349
132. F.M. Gunning-Dixon, A.M. Brickman, J.C. Cheng, and G.S. Alexopoulos Aging of cerebral white matter: a review of MRI findings Int J Geriatr Psychiatry 24 2009 109 117
133. V.S. Helgeson, P. Snyder, and H. Seltman Psychological and physical adjustment to breast cancer over 4 years: identifying distinct trajectories of change Health Psychol 23 2004 3 15
134. C.E. Jansen, C.A. Miaskowski, M.J. Dodd, and G.A. Dowling A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer Oncol Nurs Forum 34 2007 997 1005
135. M. Inagaki, E. Yoshikawa, and Y. Matsuoka Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy Cancer 109 2007 146 156
136. B.C. McDonald, S.K. Conroy, T.A. Ahles, J.D. West, and A.J. Saykin Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study J Clin Oncol 30 2012 2500 2508
137. S.M. Hosseini, D. Koovakkattu, and S.R. Kesler Altered small-world properties of gray matter networks in breast cancer BMC Neurol 12 2012 28
138. M.B. de Ruiter, L. Reneman, and W. Boogerd Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging Hum Brain Mapp 33 2012 2971 2983
139. S. Deprez, T. Billiet, S. Sunaert, and A. Leemans Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review Brain Imaging Behav 2013 Jan 18 [Epub ahead of print]
140. A. Saykin Altered brain activation following systemic chemotherapy for breast cancer: Interim analysis from a prospective study 34th Annual Meeting of International Neuropsychological Society, Boston, MA 2006
141. C. Scherling, B. Collins, J. Mackenzie, C. Bielajew, and A. Smith Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study J Clin Exp Neuropsychol 34 2012 543 560
142. I.F. Tannock, T.A. Ahles, P.A. Ganz, and F.S. van Dam Cognitive impairment associated with chemotherapy for cancer: report of a workshop J Clin Oncol 22 2004 2233 2239
143. J. Bruno, S.M. Hosseini, and S. Kesler Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors Neurobiol Dis 48 2012 329 338
144. Z.T. von, and C.M. Martin-Ruiz Telomeres as biomarkers for ageing and age-related diseases Curr Mol Med 5 2005 197 203
145. C.P. Schroder, G.B. Wisman, and S. de Jong Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation Br J Cancer 84 2001 1348 1353
146. M. Lahav, O. Uziel, and M. Kestenbaum Nonmyeloablative conditioning does not prevent telomere shortening after allogeneic stem cell transplantation Transplantation 80 2005 969 976
147. B.E. Flanary, and W.J. Streit Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes Glia 45 2004 75 88
148. Velarde MC, Demaria M, Campisi J. Senescent cells and their secretory phenotype as targets for cancer therapy. In: Extermann M, ed. Cancer and aging. From bench to clinics. Interdiscipl Top Gerontol. 2013;38:17-27
149. L.A. Gavrilov, and N.S. Gavrilova The reliability theory of aging and longevity J Theor Biol 213 2001 527 545
150. J.S. Wefel, A.K. Saleeba, A.U. Buzdar, and C.A. Meyers Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer Cancer 116 2010 3348 3356
151. J.S. Wefel, J. Vardy, T. Ahles, and S.B. Schagen International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer Lancet Oncol 12 2011 703 708
152. Y. Stern Cognitive reserve in ageing and Alzheimer's disease Lancet Neurol 11 2012 1006 1012
153. T.M. Gill, E.A. Gahbauer, L. Han, and H.G. Allore Trajectories of disability in the last year of life N Engl J Med 362 2010 1173 1180
154. H. Jim, G. Rodin, and T.A. Ahles Long-term effects of chemo on the cognitive function of cancer patients Oncology (Williston Park) 26 2012 1012
155. M.G. Falleti, A. Sanfilippo, P. Maruff, L. Weih, and K.A. Phillips The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature Brain Cogn 59 2005 60 70
156. G. Rodin, and T.A. Ahles Accumulating evidence for the effect of chemotherapy on cognition J Clin Oncol 30 2012 3568 3569
157. S. Mohile, W. Dale, and A. Hurria Geriatric oncology research to improve clinical care Nat Rev Clin Oncol 9 2012 571 578
158. H.B. Muss, L. Biganzoli, D.J. Sargent, and M. Aapro Adjuvant therapy in the elderly: making the right decision J Clin Oncol 25 2007 1870 1875
159. R.M. Friedenberg Dementia: one of the greatest fears of aging Radiology 229 2003 632 635
160. R.L. West, D.K. Bagwell, and A. Dark-Freudeman Self-efficacy and memory aging: the impact of a memory intervention based on self-efficacy Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2007 1 28
161. S. Burdette-Radoux, and H.B. Muss Adjuvant chemotherapy in the elderly: whom to treat, what regimen? Oncologist 11 2006 234 242
162. Ferguson RJ, Eastern Main Medical Center, McDonald BC, Saykin A, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. 2007;25(25):3866-70.
163. J.E. Fardell, J. Vardy, I.N. Johnston, and G. Winocur Chemotherapy and cognitive impairment: treatment options Clin Pharmacol Ther 90 2011 366 376
164. R.J. Ferguson, T.A. Ahles, and A.J. Saykin Cognitive-behavioral management of chemotherapy-related cognitive change Psychooncology 16 8 2007 772 777
165. M. Poppelreuter, J. Weis, and H.H. Bartsch Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy J Psychosoc Oncol 27 2009 274 296
166. T. Okura, B.L. Plassman, D.C. Steffens, D.J. Llewellyn, G.G. Potter, and K.M. Langa Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study J Am Geriatr Soc 58 2010 330 337
167. J.E. Fardell, J. Vardy, J.D. Shah, and I.N. Johnston Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity Psychopharmacology (Berl) 220 2012 183 193
168. P. Newhouse, K. Kellar, and P. Aisen Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial Neurology 78 2012 91 101
169. L. Lyons, M. ElBeltagy, G. Bennett, and P. Wigmore Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery PLoS One 7 2012 e30010
170. M. ElBeltagy, S. Mustafa, and J. Umka Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil Behav Brain Res 208 2010 112 117
171. S. Kohli, S.G. Fisher, and Y. Tra The effect of modafinil on cognitive function in breast cancer survivors Cancer 115 2009 2605 2616
172. L.E. Lundorff, B.H. Jonsson, and P. Sjogren Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial Palliat Med 23 2009 731 738
173. C.J. Nelson, N. Nandy, and A.J. Roth Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions Palliat Support Care 5 2007 273 280
174. A.D. Roses, A.M. Saunders, Y. Huang, J. Strum, K.H. Weisgraber, and R.W. Mahley Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease) Pharmacogenomics J 7 2007 10 28
175. H.B. Muss, D.A. Berry, and C.T. Cirrincione Adjuvant chemotherapy in older women with early-stage breast cancer N Engl J Med 360 2009 2055 2065
176. P.A. Ganz Host factors, behaviors, and clinical trials: opportunities and challenges J Clin Oncol 30 2012 2817 2819
177. K.S. Scher, and A. Hurria Under-representation of older adults in cancer registration trials: known problem, little progress J Clin Oncol 30 2012 2036 2038